摘要
肿瘤分子靶向治疗,是指在细胞分子水平上,针对已经明确的致癌位点(该位点可以是肿瘤细胞内部的一个蛋白分子,也可以是一个基因片段),来设计相应的治疗药物,药物进入体内以后靶向性选择与这些致癌位点相结合并发生作用,导致肿瘤细胞特异性死亡,而较少作用于肿瘤周围的正常组织细胞,所以分子靶向治疗又被称为“生物导弹”。分子靶向治疗的问世,不仅改变了传统化疗药物治疗模式,而且提高了某些肿瘤治愈率。根据药物的作用靶点和性质不同,本文就目前非霍奇金淋巴瘤中靶向治疗及其进展作一综述。
出处
《浙江临床医学》
2010年第3期323-325,共3页
Zhejiang Clinical Medical Journal
参考文献23
-
1Colombat P, Salles G, Brousse N, et al. Rituximab ( anti - CD20 monoclonal antibody) as single first - line therapy for patients with follicula lymphoma with a low tumor burden : clinical and molecular evaluation. Blood,2001,97:101 - 106.
-
2Czuczman MS, Fallon A, Mohr A, et al. Phase Ⅱ study of rituximab plus fludarabine in patients (pts.) with low -grade lymphoma. Blood ,2001,98 (Suppl 1 ) :601 (Abstr 2518A ).
-
3王迎,李业楠,邹德慧,王亚非,秦铁军,赵耀中,钱林生,邱录贵.美罗华联合化疗治疗侵袭性B细胞非霍奇金淋巴瘤的临床分析[J].中国肿瘤临床,2008,35(8):421-423. 被引量:11
-
4Kaufmann H, Raderer M, Wohrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood,2004,104:2269 - 2271.
-
5Leonard JP, Morion C, Jamie CK, et al. Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non - Hedgkin' s Lymphoma. J Clin Ontol,2005,23(22) :5044 -5051.
-
6Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34 - containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood ,2000,96:864 - 869.
-
7Vose JM,Wahl RL, Saleh M, et al. Muhicenter phase Ⅱ study of io- dine - 1 3 1 tositumomab for chemotherapy - relapsed/refractory lowgradeand transformed low - grade B - cell non - Hod gkin' s lymphomasJ Clin Oncol,2000,18 (6) : 1316 - 1323.
-
8Kaminski MS,Zelenetz AD, Press OW, et al. Pivotal study of iodine - 131 tositumomab for chemotherapy - refractory low - grade or transformed low - grade B - cell non - Hodgkin' s lymphomas. J Clin Oncol,2001,19:3918 - 3928.
-
9Cruczman MS, Thall A, Witzig TE, et al. Phase Ⅰ/Ⅱ study of galiximab, an anti - CD80 antibody for relapsed or refractoryfollicular lymphoma. J Clin Oneol,2005 ,23 :4390 -4398.
-
10Leonard JP, Friedberg JW. Durable Responses in Patients Treated with Galiximab ( Anti - CD80 ) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long - Term Follow - up of a Phase Ⅱ Clinical Trial. Blood. Nov,2008,112:1004.
二级参考文献9
-
1赵耀中,邹德慧,李睿,王亚非,万长春,王国蓉,麦玉洁,李桥川,李云涛,靳风艳,徐燕,林华,钱林生,邱录贵.47例晚期非霍奇金淋巴瘤临床分析及治疗策略的探讨[J].白血病.淋巴瘤,2004,13(4):195-197. 被引量:5
-
2陆文斌,金建华,顾小燕,王芳,李献文,张华,杨玉薇.CHOPE方案治疗侵袭性非霍奇金淋巴瘤(NHL)40例[J].中国肿瘤临床,2007,34(3):151-153. 被引量:9
-
3李妍,王迎,邹德慧,傅明伟,赵耀中,李新,王国蓉,邓书会,邱录贵.HyperCVAD/MA方案强化治疗31例淋巴系统肿瘤的初步临床观察[J].国际输血及血液学杂志,2007,30(2):122-127. 被引量:11
-
4Stern M,Herrmann R. Overview of monodonal antibodies in cancer therapy: present and promise[J]. Crit Rev Oncol Hematol, 2005, 54(1): 11-29
-
5Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monodonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase Ⅱ study [J]. Blood, 1998, 92(6): 1927-1932
-
6Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cydophosphamide, doxorubicin, vincristine, and predrtisone significandy improves response and time to treatment failure,but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)[J].J Clin Oncol, 2005, 23(9): 1984-1992
-
7Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mande-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine[J].J Clin Oncol, 2005, 23 (28): 7018-7028
-
8Jermann M, Jost LM, Tavema CA, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed,refractory or transformed B-cell lymphomas: results of a phase H study [J]. Ann Oncol, 2004, 15(3): 511-516
-
9Berinstein NL. Principles of maintenance therapy [J]. Leuk Res, 2006, 30(Suppl 1): S3-S10
共引文献10
-
1杜芹,杨锡贵.利妥昔单抗联合化疗治疗复发B细胞恶性淋巴瘤的回顾性分析[J].中国肿瘤临床,2009,36(4):203-206. 被引量:5
-
2易树华,徐燕,邹德慧,安刚,赵耀中,齐军元,邱录贵.骨髓侵犯和不同治疗方案对弥漫大B细胞淋巴瘤患者预后的影响[J].中华血液学杂志,2009,30(5):307-312. 被引量:7
-
3陈桂秋,卢一艳,王丽萍,牛春波,张秀茹.乳腺癌分子分型研究进展[J].中国实验诊断学,2011,15(6):1130-1133. 被引量:14
-
4商安芳,郭静明,朱磊,王海燕,潘莉萍,唐芳容,田铭.美罗华加沙利度胺联合化疗治疗侵袭性B细胞非霍奇金淋巴瘤的疗效分析[J].内科急危重症杂志,2011,17(6):366-368. 被引量:7
-
5沈秋丹,蔡伟波,刘仁涛,吕明恩,袁慕知,韩迎利.利妥昔单抗联合化疗治疗回盲部弥漫大B细胞淋巴瘤的临床分析[J].临床药物治疗杂志,2012,10(3):10-13. 被引量:4
-
6姬卫国,张明智,王祥麒,王俊涛.利妥昔单抗注射液对CD20阳性淋巴瘤患者血清血管内皮生长因子和乳酸脱氢酶水平的影响及疗效[J].中国老年学杂志,2012,32(19):4155-4156. 被引量:4
-
7戴秋新,徐昕,孟文俊,杨建刚.美罗华联合ICE方案治疗复发非霍奇金淋巴瘤疗效观察[J].实用临床医药杂志,2012,16(21):73-74. 被引量:1
-
8杨秋敏.美罗华联合化疗在B细胞非霍奇金淋巴瘤治疗中的临床疗效评价[J].中国伤残医学,2013,21(12):38-40. 被引量:1
-
9刘江华.利妥昔单抗注射液辅助治疗儿童非霍奇金淋巴瘤[J].深圳中西医结合杂志,2018,28(23):24-26. 被引量:2
-
10奚和明.美罗华联合化疗在B细胞非霍奇金淋巴瘤治疗中的临床疗效及安全性评估[J].中国实用医药,2015,10(36):135-136. 被引量:2
同被引文献37
-
1李伟,曾建成.骨肿瘤靶向治疗系统研究进展[J].华西医学,2008,23(5):1225-1226. 被引量:3
-
2吴强,杨述华,叶树楠.RNA干扰沉默缺氧诱导因子-1α治疗骨肉瘤的实验研究[J].华中科技大学学报(医学版),2005,34(3):280-280. 被引量:1
-
3王燕,汪睿,乔慧,李晋云,彭挺生,李扬,张萌,梁惠珍,丘钜世.缺氧反应元件启动子表达反义血管内皮生长因子(VEGF)_(165)cDNA靶向性抑制骨肉瘤细胞VEGF表达[J].中华病理学杂志,2005,34(9):588-591. 被引量:6
-
4刘国辉,叶树楠,杨述华.肿瘤靶向DNA载体转铁蛋白-多聚乙烯亚胺体外转染[J].中华实验外科杂志,2006,23(12):1519-1521. 被引量:5
-
5Campanacci M.Bone and soft tissue tumors:clinical features,imaging,pathology and treatment.2nd ed.New York,Springer,1999:464-491.
-
6Jaffe N.Osteosarcoma:review of the past,impact on the future.The American experience.J Cancer Treat Res,2010,152:239-262.
-
7Naruse T,Nishida Y,Hosono K,et al.Meloxicam inhibits osteosarcoma growth,invasiveness and metastasis by COX-2-dependent and independent routes.J Canrcinogenesis,2006,27:584-592.
-
8Xu Z,Choudhary S,Voznesensky O,et al.Overexpression of Cox-2 in human osteosareoma cells decrease proliferation and increases apoptosis.J Cancer Res,2006,66:6657-6664.
-
9Rodriguez NI,Hoots WK,Koshkina NV,et al.COX-2 expression correlates with survival in patients with osteosarcoma lung metastases.J Pediatr Hematol Oncol,2008,30:507-512.
-
10Oda Y,Yamamoto H,Tamiya S,et al.CXCR4 and VEGF expression in the primary site and metastatic site of human osteosarcoma:analysis within a group of patients all of whom developed lung metastasis.J Mod Pathol,2006,19:738-745.
-
1郭跃武.分子靶向治疗——乳腺癌患者的新希望[J].自我保健,2009(4):45-45.
-
2白向艳,罗丹阳,苏乌云.结直肠癌分子靶向治疗的研究进展[J].山东医药,2016,56(40):107-109. 被引量:5
-
3储大同.单克隆抗体——肿瘤靶向治疗的新方向[J].中华肿瘤杂志,2004,26(3):189-190. 被引量:2
-
4姚秀.生物靶向治疗口腔癌研究进展[J].医学美学美容(中旬刊),2012(8):77-77.
-
5朴素宙,朴龙镇.“三阴性”乳腺癌分子靶向治疗的研究进展[J].中国妇幼保健,2011,26(30):4787-4789. 被引量:4
-
6李恩孝,施璠,吴胤瑛.靶向抗VEGFR治疗恶性肿瘤的研究进展[J].现代肿瘤医学,2006,14(2):234-236. 被引量:6
-
7李耀东,郭顺林,赵鹏普,王文辉,张皓.进展期胃癌的X线表现与血管内皮生长因子及增殖细胞核抗原表达的关系[J].中国医学影像技术,2004,20(2):264-267.
-
8席思川.纤维母细胞的生长调控[J].中国烧伤创疡杂志,1994(1):5-7. 被引量:1
-
9李冬生.甲状腺肿瘤普外科手术治疗的临床特点研究[J].吉林医学,2015,36(8):1552-1553. 被引量:7
-
10滕颖(综述),沈周俊(审校).膀胱肿瘤灌注治疗的现状[J].国际泌尿系统杂志,2009,29(3):339-342.